Aleksandrs Zavoronkovs
Founder & Chief Executive Officer @ Insilico Medicine
London, United Kingdom
Aleksandrs Zavoronkovs is a seed investor at Insilico Medicine in London focused on Biotechnology and Health Care. Aleksandrs Zavoronkovs is based out of Cambridge, Massachusetts, and is the Founder, Chief Executive Officer and Chief Business Officer of Insilico Medicine and also works as Chairman of the Board. Aleksandrs previously worked at Deep Longevity as Chief Longevity Officer. Aleksandrs Zavoronkovs attended the Queen's University.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Aleksandrs Zavoronkovs invests in
Stages Aleksandrs Zavoronkovs invests in
Countries Aleksandrs Zavoronkovs invests in
Round sizes
Round size
- Series D
- $35M–$60M
Investment Focus
Industry
- Biotechnology 2 (67%)
- Health Care 1 (33%)
- Pharmaceutical 1 (33%)
- Artificial Intelligence 1 (33%)
Stage
- Seed 1 (33%)
- Series D 1 (33%)
Country
- Romania 1 (33%)
- Hong Kong 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
The Cat Health Company
|
The Cat Health Company, which focuses on advancing feline longevity research to prevent or delay age-related illnesses in cats. | $1.2M / Seed / Oct 02, 2025 | |
Insilico Medicine
|
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and,unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. | $35M / Series D / Aug 10, 2022 | |
|
Insilico Medicine
|
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and,unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. | $60M / Series D / Jun 06, 2022 |
Co-Investors
Qiming Venture Partners
4 deals together
B Capital
2 deals together
BHR Partners
2 deals together
Bold Capital Partners
2 deals together
Deerfield
2 deals together
Pavilion Capital
2 deals together
About Insilico Medicine
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and,unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
Insilico Medicine Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Aleksandrs Zavoronkovs
Founder & Chief Executive Officer
|
|||
Alex Aliper
President
|
|||
Evgeny Izumchenko
Senior Advisor
|
|||
Feng Ren
Chief Scientific Officer and Head of Drug R&D; Executive Director
|
|||
Halle Zhang
Vice President of Clinical Development – Oncology
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Aleksandrs Zavoronkovs invest in?
Aleksandrs Zavoronkovs invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Seed and Series D stage. Most of the 3 investments tracked by Shizune back companies in Romania. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Aleksandrs Zavoronkovs's check size?
Aleksandrs Zavoronkovs typically joins rounds of $35M–$60M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Aleksandrs Zavoronkovs participates in.
When did Aleksandrs Zavoronkovs last invest?
The most recent investment recorded for Aleksandrs Zavoronkovs closed in Oct 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
